Agios Pharmaceuticals, Inc.

Good morning and welcome to AGO's second quarter 2022 conference call. At this time, all participants are listening on the mode. There will be a question and answer session at the end of the call. Please be advised that this call is being recorded at AGO's request. I would now like to turn the conference over to Holly Manning, Senior Director of Investor Relations. Please go ahead.

Thank you, Operator. Good morning, everyone, and welcome to AGIOS's second quarter 2022 conference call. You can access slides for today's call by going to the investor section of our website, agios.com. With me on the call today with prepared remarks are Dr. Jackie Faust, our Chief Executive Officer, Dr. Sarah Guins, our Chief Medical Officer and Head of Research and Development, Richa Poddar, our Chief Commercial Officer, and Jonathan Biller, our Chief Financial Officer and Head of Corporate Affairs. Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. With that, I will turn the call over to Jack.

Thanks, Holly. Good morning, everyone, and thanks for joining our second quarter 2022 results call. The first half of 2022 has been remarkably productive across all facets of our business. I've continued to be impressed by the focused execution of the Agios team and their connection to each other and our vision of making an impact on the lives of patients. In February, our world-class commercial organization launched our first genetically defined disease medicine, Pyrocon, which is the first FDA-approved therapy to treat pyruvate kinase deficiency and the first ever approved PK activator. Today, we report impressive commercial performance for our first full quarter of launch, which Richa will cover in more detail. Our exceptional clinical team initiated two pediatric PK deficiency pivotal studies, as well as a sickle cell disease cohort of the AG946 phase one trial, all while operationalizing the AG946 MDS study and continuing to advance site activation and patient enrollment across three pivotal studies of pyrokin in thalassemia and sickle cell disease. In May, we made the tough decision to evolve our research organization, which has led to the ongoing integration of our R&D teams and enhanced our research focus and business development activities. And in June, we had a robust presence at the European Hematological Association meeting in Vienna with broad preclinical, translational, and clinical updates across the programs. Sarah will review our preclinical and clinical programs momentarily. A highlight for me occurred a few weeks ago when Agios employees came together for our first company off-site since the start of the pandemic two and a half years ago. It was an incredible reminder of the expansive talent we have at Agios and the interconnected culture that continues to thrive through the dynamic evolution of our business. Turning to slide five, a few weeks ago we announced that as of Monday, August 8th, I will transition to the role of Chair of the Board of Directors and Brian Goff will become the new Chief Executive Officer of Agios. Brian has vast experience in hematology, rare diseases, and commercial and operational leadership cultivated over the course of 30 years at global biopharmaceutical companies. I strongly believe that he is the right leader to guide Augios through its next chapter. As I reflect on my time as CEO, I'm proud of the bold, strategic decisions that we made as a team, our resiliency in the face of a global pandemic, and the individual lives that we have touched through the medicines we've created. My confidence in the Agios team and its ability to make a positive impact on the world remains steadfast, and it's for that reason that I'm so excited to continue to play a role in that mission as chair of our board. Starting Monday, I'll be focused on helping Brian orchestrate a smooth transition into his role as CEO, serving as a founding board and point of reference while also giving him space to learn and make decisions. I also look forward to working with my colleagues on our board to fully leverage and evolve our collective board skill set so that we can continue to be a great resource for Augeos and the management team as we move into a bright future as a rare and genetically defined diseases focused company. Standing here today, Augeos is operating from a position of immense strength with a first in class commercial launch, five pivotal trials underway, multiple early stage clinical studies planned or underway, a promising preclinical pipeline, and an enviable balance sheet that provides significant optionality for the future growth of the business. I look forward to continuing to be part of this amazing team, and I thank each of you for your support of Augeos now and in the future. With that, I'll turn it over to Sarah.